Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 399
Filter
1.
Zhongguo Dongmai Yinghua Zazhi ; 30(1):15-20, 2022.
Article in Chinese | Scopus | ID: covidwho-20245073

ABSTRACT

Aim To analyze the differences in clinical characteristics and outcomes of coronavirus disease 2019 (COVID-19) critically ill patients with or without vascular calcification. Methods COVID-19 critically ill patients admitted to the intensive care unit of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology in February 2020 were analyzed retrospectively. According to the chest CT findings, the patients were divided into vascular calcification group and non-vascular calcification group. The vascular calcification group was further divided into aortic calcification group, coronary calcification group and simultaneous calcification group (both aorta and coronary artery calcification). The clinical characteristics and outcomes of patients were compared in different groups. Results Compared with the non-vascular calcification group, the patients in the vascular calcification group were older and had a higher proportion of hypertension and coronary heart disease, which showed higher levels of leukocyte count, neutro-phil count, C-reactive protein, globulin, lactate dehydrogenase, international normalized ratio, D-dimer, creatinine, crea-tine kinase-MB, high-sensitivity cardiac troponin, myohemoglobin and N-terminal pro-B-type natriuretic peptide, lower levels of lymphocyte count, platelet count, albumin, estimated glomerular filtration rate, and higher risk of death. Compared with aortic calcification group, the outcomes of coronary calcification group and simultaneous calcification group were worse. Conclusion Vascular calcification, especially coronary artery calcification, may be a risk factor for poor prognosis in COVID-19 critically ill patients. © 2022, Editorial Office of Chinese Journal of Arteriosclerosis. All rights reserved.

2.
Zhongguo Dongmai Yinghua Zazhi ; 30(10):884-889, 2022.
Article in Chinese | Scopus | ID: covidwho-20244585

ABSTRACT

Aim To explore the myocardial damage, abnormal electrocardiogram characteristics of patients infected with SARS-CoV-2 Omicron variant in Zhuhai. Methods 84 patients with SARS-CoV-2 Omicron variant (Omicron variant group) admitted to the Fifth Affiliated Hospital of Sun Yat-sen University from January 13 to March 20, 2022 were included, and 88 patients with non SARS-CoV-2 Omicron variant (non-Omicron variant group) from January 17 to February 17, 2020 were included. A retrospective study was conducted to compare myocardial damage, abnormal electrocardiogram and clinical characteristics between the two groups. Results The mean age of patients in Omicron variant group was smaller than that in non-Omicron variant group [(36. 6±15. 6) years vs. (49. 8±14. 3) years, P<0. 01], and the proportion of patients with body temperature, systolic blood pressure and fever at admission was lower than that of non-Omicron variant group (P<0. 05). The neutrophil / lymphocyte ratio [(2. 93 (3. 03, 5. 81) vs. 7. 06 (2. 32, 11. 27), P<0. 001], interleukin-2 (IL-2) and interleukin-6 (IL-6) levels in Omicron variant group were significantly lower than those in non-Omicron variant group (P<0. 01). Cardiac troponin I (cTnI) was negative in Omicron variant group, and the concentrations of cTnI, creatine kinase-MB isozyme (CK-MB) and N-terminal pro-brain natriuretic peptide (NT-proB-NP) and the proportion of patients with elevated levels were significantly lower than those of non-Omicron variant group (P<0. 01). The incidence of abnormal electrocardiogram in Omicron variant group was also significantly lower than that in non-Omicron variant group (25. 0% vs. 42. 0%, P = 0. 001), sinus tachycardia, atrial premature beats and T wave changes were the main symptoms. Atrial premature beats, T wave changes, ST segment depression and bundle branch block were the main symptoms in non-Omicron variant group. Conclusions The patients infected with SARS-CoV-2 Omicron variant in Zhuhai may not have obvious myocardial damage because most of the patients have been vaccinated with COVID-19 vaccine. The incidence of abnormal electrocardiogram is also significantly lower than that of non-Omicron variant group, mainly sinus tachycardia, atrial premature beats and T wave changes. © 2022, Editorial Office of Chinese Journal of Arteriosclerosis. All rights reserved.

3.
Front Public Health ; 11: 1184262, 2023.
Article in English | MEDLINE | ID: covidwho-20244832

ABSTRACT

Objective: To report the otologic symptoms that present in patients with COVID-19 infection and investigate the pathogenic characteristics during the period of the pandemic. Materials and methods: This cross-sectional descriptive study included participants with COVID-19 infection. COVID-19 infection was verified in these patients by nucleic acid test or antigen test. An online questionnaire was developed to analyze the association between the COVID-19 pandemic and the characteristics of otologic symptoms. Results: This study included 2,247 participants, of which nearly half had one or more otologic symptoms. The presents of otologic symptoms were associated with gender (OR = 1.575, p < 0.0001), age (OR = 0.972, p < 0.0001), and occupation (healthcare worker: p < 0.0001; personnel of enterprises or institutions: OR = 1.792, p < 0.0001; student: OR = 0.712, p < 0.044). The otologic symptoms following COVID-19 infection in order were vertigo (25.95%), tinnitus (19.05%), otalgia (19.00%), aural fullness (17.18%), hearing loss (11.62%), otorrhea (1.25%), and facial paralysis (0.27%). Conclusion: The present study shows that otologic symptoms are common among the COVID-19 infected participants and that these symptoms mostly recover spontaneously. During the corona-virus pandemic, the involvement of the cochleovestibular system and facial nerve should not be overlooked while treating the COVID-19 infected individuals.


Subject(s)
COVID-19 , Nucleic Acids , Humans , COVID-19/epidemiology , Cross-Sectional Studies , Pandemics , Health Personnel
4.
Int J Gen Med ; 16: 2305-2312, 2023.
Article in English | MEDLINE | ID: covidwho-20244496

ABSTRACT

Objective: This study aimed to analyze the epidemiological and clinical characteristics of measles in Jinan, Shandong, China, over a 32-year stage to facilitate measles prevention in the future. Methods: Data on measles cases from 1991 to 2022 were obtained from the public health department and medical records of patients at Shandong Public Health Clinical Center. Retrospective analysis was conducted on the distribution of measles cases in different years, months, and age groups, and observation of the differences in clinical manifestations and complications among different age groups. Results: From January 1991 to December 2022, 7531 measles cases were recorded at Shandong Public Health Clinical Center. During the 32-year period, there were two outbreaks of measles in 2008 and 2016, respectively. During the COVID-19 pandemic period from 2020 to 2022, the number of cases reached the lowest point in the past 30 years. The number and percentage of cases in the 0-1y groups was significantly higher than in other age groups, and 97.75% patients in this group did not receive measles vaccine. Complications such as pneumonia and myocarditis appeared more frequent in patients under 12 years of age, but liver function damage is more common in adult patients. Conclusion: Although the measles epidemic has been greatly controlled since the use of measles vaccine, intermittent outbreaks still exist, so there is still a long way to go to eliminate measles. The proportion of infants under the age of 1 without measles vaccine and adults over 24 years old accounts for nearly 80% of the total. This group of people should be of concern, and feasible measures should be designated to protect these susceptible populations.

5.
Healthcare (Basel) ; 11(11)2023 Jun 02.
Article in English | MEDLINE | ID: covidwho-20243918

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is among the top global health crises. As confirmed by the Vietnam Ministry of Health on 25th January 2023, Vietnam had a cumulative total of more than 11.52 million COVID-19 patients, including 10.61 million recoveries and 43,186 deaths. OBJECTIVES: This study aimed to describe the clinical and subclinical characteristics, treatment progress, and outcomes of 310 cases of SARS-CoV-2 infection. METHODS: A total of 310 patients with medical records of SARS-CoV-2 were admitted to Can Tho City Hospital of Tuberculosis and Lung Diseases, Can Tho city, Vietnam, between July 2021 and December 2021. Demographic and clinical data, including laboratory examinations, of all the patients were collected and analyzed. RESULTS: The median duration of hospital stay was 16.4 ± 5.3 days. There were 243 (78.4%) patients with clinical symptoms of COVID-19 and 67 (21.6%) patients without clinical symptoms. The common symptoms included cough (71.6% of 310 patients), fever (35.4%), shortness of breath (22.6%), sore throat (21.4%), loss of smell/taste (15.6%), and diarrhea (14.4%). Regarding treatment outcomes, 92.3% of the patients were discharged from the hospital, 1.9% of the patients suffered a more severe illness and were transferred to a higher-level hospital, and 5.8% of the patients died. The RT-PCR results were negative in 55.2% of the patients, and 37.1% of the patients had positive RT-PCR results with Ct values of >30 on the discharge/transfer day. Multivariate logistic regression analyses showed that comorbidity and decreased blood pH were statistically significantly related to the treatment outcomes of the patients with COVID-19 (p < 0.05). CONCLUSIONS: This study provides useful information (i.e., the clinical characteristics and treatment outcomes) on the COVID-19 pandemic in Vietnam during its biggest outbreak; the information may be used for reference and for making improvements in the handling of future health crises.

6.
China CDC Wkly ; 5(23): 511-515, 2023 Jun 09.
Article in English | MEDLINE | ID: covidwho-20234526

ABSTRACT

What is already known about this topic?: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, the clinical manifestations resulting from different SARS-CoV-2 variants may demonstrate significant variation. What is added by this report?: We conducted a comparative analysis of the clinical features associated with SARS-CoV-2 Omicron subvariants BF.7.14 and BA.5.2.48 infections. The results of our study indicate that there are no substantial differences in clinical manifestations, duration of illness, healthcare-seeking behaviors, or treatment between these two subvariants. What are the implications for public health practice?: Timely identification of alterations in the clinical spectrum is crucial for researchers and healthcare practitioners in order to enhance their comprehension of clinical manifestations, as well as the progression of SARS-CoV-2. Furthermore, this information is beneficial for policymakers in the process of revising and implementing appropriate countermeasures.

7.
Oncology in Clinical Practice ; 19(2):69-75, 2023.
Article in English | Web of Science | ID: covidwho-20231230
8.
China Tropical Medicine ; 21(3):255-258, 2021.
Article in Chinese | EMBASE | ID: covidwho-2327351

ABSTRACT

Objective To analyze the clinical features of patients with coronavirus disease 2019COVID-19in Wuhan, and we provide reference for further prevention and control of the disease. Methods We collected the clinical data of patients with COVID-19 in Dongxihu Shelter Hospital of Wuhan from February 7 to March 6, 2020. The main symptoms, blood test results, lung CT results, and nucleic acid negative conversion were analyzed. Results A total of 654 patients were included, 17526.76%were mild, and 47973.24%were general. There were 344 males (52.60%), and 310 females (47.40%). The patients were with a mean age of49.36+/-10.30years, and 97 patients (14.83%) with a history of hypertension, 51 patients (7.80%) had a history of diabetes. The main clinical symptoms were fever with 547(83.64%) patients, 186 cases (28.44%) had chills, 15 cases (2.29%) had shiver, 342(52.29%) had fatigue symptoms, 413(63.15%) had cough, 137(20.95%) had chest tightness, and 109(16.67%) had diarrhea during the course of the disease. Blood routine tests of 395 patients, the white blood cell count (WBC) was (4.12+/-1.46)x109/L. The total white blood cell count was normal in 378 cases(95.70%), increased in 7(1.77%), and decreased in 10(2.53%). The lymphocyte percentage was (23.10+/-10.02)%, lymphocyte1.06+/-0.37x109/L. The percentage and count of lymphocyte were low. All the 654 cases were examined by CT, 175 cases (26.76%) showed normal lung CT, 422 cases (64.52%) showed patchy or segmental ground-glass opacity, and 57 cases (8.72%) showed multilobar consolidation, ground-glass shadow coexisted with consolidation or streak shadow. The interval between positive nucleic acid test before admission and negative test after admission was as short as 5 days and as long as 24 days, the average was (12.35+/-3.73) days. Conclusion Fever, coughing, and fatigue are the main symptoms in patients with COVID-19. The typical lung CT findings can be used as the basis for clinical diagnosis and disease evaluation. Patients with mild and common type had better prognosis.Copyright © 2021 Editorial Office of Chinese Journal of Schistosomiasis Control. All rights reserved.

9.
Eur Geriatr Med ; 14(3): 465-476, 2023 06.
Article in English | MEDLINE | ID: covidwho-2322503

ABSTRACT

BACKGROUND AND OBJECTIVES: Depression is highly prevalent in older adults, especially in those with dementia. Trazodone, an antidepressant, has shown to be effective in older patients with moderate anxiolytic and hypnotic activity; and a common off-label use is rising for managing behavioral and psychological symptoms of dementia (BPSD). The aim of the study is to comparatively assess the clinical profiles of older patients treated with trazodone or other antidepressants. METHODS: This cross-sectional study involved adults aged ≥ 60 years at risk of or affected with COVID-19 enrolled in the GeroCovid Observational study from acute wards, geriatric and dementia-specific outpatient clinics, as well as long-term care facilities (LTCF). Participants were grouped according to the use of trazodone, other antidepressants, or no antidepressant use. RESULTS: Of the 3396 study participants (mean age 80.6 ± 9.1 years; 57.1% females), 10.8% used trazodone and 8.5% others antidepressants. Individuals treated with trazodone were older, more functionally dependent, and had a higher prevalence of dementia and BPSD than those using other antidepressants or no antidepressant use. Logistic regression analyses found that the presence of BPSD was associated with trazodone use (odds ratio (OR) 28.4, 95% confidence interval (CI) 18-44.7 for the outcome trazodone vs no antidepressants use, among participants without depression; OR 2.17, 95% CI 1.05-4.49 for the outcome trazodone vs no antidepressants use, among participants with depression). A cluster analysis of trazodone use identified three clusters: cluster 1 included mainly women, living at home with assistance, multimorbidity, dementia, BPSD, and depression; cluster 2 included mainly institutionalized women, with disabilities, depression, and dementia; cluster 3 included mostly men, often living at home unassisted, with better mobility performance, fewer chronic diseases, dementia, BPSD, and depression. DISCUSSION: The use of trazodone was highly prevalent in functionally dependent and comorbid older adults admitted to LTCF or living at home. Clinical conditions associated with its prescription included depression as well as BPSD.


Subject(s)
COVID-19 , Dementia , Trazodone , Male , Humans , Female , Aged , Aged, 80 and over , Trazodone/adverse effects , Dementia/epidemiology , Cross-Sectional Studies , Antidepressive Agents/therapeutic use
10.
Health Serv Insights ; 16: 11786329231174745, 2023.
Article in English | MEDLINE | ID: covidwho-2326762

ABSTRACT

Objective: Long-term care (LTC) homes ("nursing homes") were challenged during the first year of the COVID-19 pandemic in Canada. The objective of this study was to measure the impact of the COVID-19 pandemic on resident admission and discharge rates, resident health attributes, treatments, and quality of care. Design: Synthesis analysis of "Quick Stats" standardized data table reports published yearly by the Canadian Institute for Health Information. These reports are a pan-Canadian scorecard of LTC services rendered, resident health characteristics, and quality indicator performance. Setting and participants: LTC home residents in Alberta, British Columbia, Manitoba, and Ontario, Canada that were assessed with the interRAI Minimum Data Set 2.0 comprehensive health assessment in fiscal years 2018/2019, 2019/2020 (pre-pandemic period), and 2020/2021 (pandemic period). Methods: Risk ratio statistics were calculated to compare admission and discharge rates, validated interRAI clinical summary scale scores, medication, therapy and treatment provision, and seventeen risk-adjusted quality indicator rates from the pandemic period relative to prior fiscal years. Results: Risk of dying in the LTC home was greater in all provinces (risk ratio [RR] range 1.06-1.18) during the pandemic. Quality of care worsened substantially on 6 of 17 quality indicators in British Columbia and Ontario, and 2 quality indicators in Manitoba and Alberta. The only quality indicator where performance worsened during the pandemic in all provinces was the percentage of residents that received antipsychotic medications without a diagnosis of psychosis (RR range 1.01-1.09). Conclusions and implications: The COVID-19 pandemic has unveiled numerous areas to strengthen LTC and ensure that resident's physical, social, and psychological needs are addressed during public health emergencies. Except an increase in potentially inappropriate antipsychotic use, this provincial-level analysis indicates that most aspects of resident care were maintained during the first year of the COVID-19 pandemic.

11.
Front Aging Neurosci ; 15: 1138418, 2023.
Article in English | MEDLINE | ID: covidwho-2327140

ABSTRACT

Background: Clinical manifestations of Parkinson's disease (PD) after Corona Virus Disease 2019 (COVID-19) infection are poorly investigated. Objective: We aimed to explore the clinical features and outcomes of hospitalized PD patients with COVID-19. Methods: A total of 48 PD patients and 96 age-and sex-matched non-PD patients were included. Demographics, clinical characteristics and outcomes were compared between two groups. Results: PD patients with COVID-19 were elderly (76.69 ± 9.21 years) with advanced stage (H-Y stage 3-5 as 65.3%). They had less clinical symptoms (nasal obstruction, etc.), more proportions of severe/critical COVID-19 clinical classification (22.9 vs. 1.0%, p < 0.001), receiving oxygen (29.2 vs. 11.5%, p = 0.011), antibiotics (39.6 vs. 21.9%, p = 0.031) therapies, as well as longer hospitalization duration (11.39 vs. 8.32, p = 0.001) and higher mortality (8.3% vs. 1.0%, p = 0.001) relative to those without PD. Laboratory results showed that the PD group had higher white blood cell counts (6.29 vs. 5.16*109, p = 0.001), neutrophil-to-lymphocyte ratio (3.14 vs. 2.11, p < 0.001) and C-reactive protein level (12.34 vs. 3.19, p < 0.001). Conclusion: PD patients with COVID-19 have insidious clinical manifestation, elevated proinflammatory markers and are prone to the development of severe/critical condition, contributing to a relatively poor prognosis. Early identification and active treatment of COVID-19 are pivotal to advanced PD patients during the pandemic.

12.
Infectious Diseases and Immunity ; 3(2):75-82, 2023.
Article in English | Scopus | ID: covidwho-2319880

ABSTRACT

Background Delta and Omicron are two main variants that have been prevalent since 2021. However, the Omicron variant of severe acute respiratory syndrome coronavirus 2 shows a less severe clinical presentation and high transmissibility. Therefore, we carried out this retrospective study to evaluate Omicron severity compared with the Delta variant and further comprehend the differences in clinical characteristics in patients with the Omicron variant. Methods We extracted clinical data and compared clinical severity, symptoms, vaccination status, laboratory parameters, viral shedding time, and computed tomography (CT) imaging between the two groups of patients, which included 109 COVID-19 cases with the Delta variant and 183 cases with the Omicron variant, from January 19 to April 1, 2022, in Beijing Ditan Hospital. In addition, the Beijing Center for Disease Prevention and Control conducted whole-genome sequencing. Results We obtained 94 strains of variants of concern/Delta and 110 strains of variants of concern/Omicron. For the 110 Omicron strains, three were assigned as BA.1.1, 53 as BA.2, and 54 as BA.2.2. Among patients with the Delta variant, 54% (59/109) were moderate, which was significantly higher than that of patients with the Omicron variant (7% (12/183), P < 0.001). The number of patients with mild symptoms in the Omicron group was significantly higher than in the Delta group (80% vs. 35%, P < 0.001). Compared with the Omicron group, patients with underlying diseases or obesity, 60 years or older, or unvaccinated in the Delta group had more severe disease, and there was a significant difference between the two groups. The viral shedding time in the Omicron group was shorter than in the Delta group ((11.9 ± 5.9) vs. (14.0 ± 5.8) days, P = 0.003). Among the 183 patients in the Omicron group, 104 (57%) had dry or sore throat symptoms, more than those in the Delta group (34% (37/109);P < 0.001). In the Delta group, patients in the moderate group had more fever and cough symptoms than those in the mild group. The remission time of CT imaging in the Omicron group was shorter than in the Delta group ((9.0 ± 5.2) vs. (13.2 ± 4.2) days, P = 0.018). Conclusions Patients with Delta variants are more likely to have pneumonia, mainly with fever and cough symptoms, while patients with the Omicron variant are mostly mild, with more prominent dry or sore throat symptoms. In addition, patients with the Omicron variant have a short viral shedding time and rapid absorption of pneumonia. © Wolters Kluwer Health, Inc. All rights reserved.

13.
Medical Journal of Wuhan University ; 43(6):885-890, 2022.
Article in Chinese | Scopus | ID: covidwho-2316738

ABSTRACT

Objective: To provide a basis for the early identification and treatment of severe and critical coronavirus disease 2019 (COVID - 19) by analyzing the clinical characteristics of the death cases. Methods: We retrospectively analyzed the clinical characteristics of 71 COVID - 19 cases which died during hospitalization. The clinical data included general data, underlying disease, clinical manifestation, biochemical laboratory examination, imaging examination, complications, and treatment, then the influencing factors of in - hospital survival were analyzed. Results: Most of the 71 patients were ≥60 years old (78. 9%) and had underlying diseases (74. 6%), in which hypertension ranked first, and fever was the most common first symptom. Biochemical laboratory tests showed that D-Dimer and C-reactive protein maintained at high levels during hospitalization, and lymphocyte count declined. Leukocyte/neutrophil counts, neutrophil to lymphocyte ratio, procalcitonin, creatine kinase, and lactate dehydrogenase increased. The main imaging features of the dead cases were the multifocal ground glass changes and consolidation of the lungs. The most common complications were acute respiratory distress syndrome (89. 9%), shock (34. 3%), and acute myocardial injury (30. 4%). 90% of the patients received auxiliary ventilation, and the decrease of blood oxygen saturation and the increase of procalcitonin may be the risk factors for shorter in-hospital survival. Conclusion: Severe and critical COVID-19 patients show different characteristics in clinical manifestations, biochemical laboratory examination, imaging examination, complications, and treatment reactions, which need early identification and treatment, and bewaring of acute respiratory distress syndrome and multiple organs failure. © 2022 Editorial Board of Medical Journal of Wuhan University. All rights reserved.

14.
Int J Infect Dis ; 130: 31-37, 2023 May.
Article in English | MEDLINE | ID: covidwho-2314050

ABSTRACT

OBJECTIVES: To analyze the clinical characteristics and outcomes of admitted patients with the hospital- versus community-manifested COVID-19 and to evaluate the risk factors related to mortality in the first population. METHODS: This retrospective cohort included consecutive adult patients with COVID-19, hospitalized between March and September 2020. The demographic data, clinical characteristics, and outcomes were extracted from medical records. Patients with hospital-manifested COVID-19 (study group) and those with community-manifested COVID-19 (control group) were matched by the propensity score model. Logistic regression models were used to verify the risk factors for mortality in the study group. RESULTS: Among 7,710 hospitalized patients who had COVID-19, 7.2% developed symptoms while admitted for other reasons. Patients with hospital-manifested COVID-19 had a higher prevalence of cancer (19.2% vs 10.8%) and alcoholism (8.8% vs 2.8%) than patients with community-manifested COVID-19 and also had a higher rate of intensive care unit requirement (45.1% vs 35.2%), sepsis (23.8% vs 14.5%), and death (35.8% vs 22.5%) (P <0.05 for all). The factors independently associated with increased mortality in the study group were increasing age, male sex, number of comorbidities, and cancer. CONCLUSION: Hospital-manifested COVID-19 was associated with increased mortality. Increasing age, male sex, number of comorbidities, and cancer were independent predictors of mortality among those with hospital-manifested COVID-19 disease.

15.
Health Sci Rep ; 6(5): e1225, 2023 May.
Article in English | MEDLINE | ID: covidwho-2316553

ABSTRACT

Background: In December 2019, many cases of COVID-19 were reported in Wuhan City, Hubei Province, China. In the following 3 months, the disease out broke in China. Preisolation measures was used to screen out COVID-19 patients in the pediatric respiratory ward of our hospital. Aims: To investigate the new measures for screening COVID-19 patients and to analyze the clinical features of children with suspicious COVID-19. Methods: A total of 50 preisolated children with suspicious COVID-19 who were admitted to our hospital in Mianyang, China, between January 28 and March 5, 2020, were included. Patients presented with fever and cough or fever accompanied by vomiting and diarrhea. A detailed epidemiological history screening was performed. A real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) was used to detect SARS-COV-2 nucleic acid. Low-dose chest computed tomography (CT) was applied when pneumonia was suspicious. Routine blood tests were performed to rule out COVID-19. Patients' data were collected, and the basic clinical features, epidemiological history, clinical manifestations, auxiliary examination results, and outcomes were analyzed and summarized. Results: No definite cases were detected, while two patients were suspected of having COVID-19. The pathogenic results of the 50 patients mainly included Mycoplasma pneumoniae, followed by Epstein-Barr virus, and rotavirus. Thirty-five patients suffered from bronchopneumonia. The preisolated patients had similar clinical and epidemiological characteristics as patients with fever, cough, vomiting, and diarrhea. Conclusions: Preisolation measures combined with pathogen screening can minimize the risk of hospital-acquired infections by preventing patients with suspicious COVID-19 from contacting other patients before they are explicitly excluded. Clinical analysis of the patients was helpful for clinical nursing management.

16.
Galicia Clinica ; 83(3):18-27, 2022.
Article in English | Web of Science | ID: covidwho-2308602

ABSTRACT

Objective: To evaluate the comorbidities in hospitalized patients with COVID-19 and identify which ones are associated with severe COVID-19 disease and/or in-hospital mortality. Methods: Unicenter retrospective cohort study was performed. All patients admitted with confirmed COVID-19 from March 1 to May 31, 2020 were included consecutively. A descriptive analysis of comorbidities at admission was made. We evaluated what comorbidities are associated with in-hospital mortality and/or severe COVID-19 disease using a binary logistic regression model. Results: A total of 336 patients were included in the study: 284 (84,5%) were discharged and 52 (15,5%) died during hospitalization. The diagnosis of COVID-19 was made by SARS-CoV-2 polymerase chain reaction in 317 patients (94%). Mean age was 66 + 14 years, 58% were men and Charlson Comorbidity Index was 1. In multivariate analysis, age >65 years (OR 2,65;95%CI 1,15 to 6,10;p 0,021), male sex (OR 3,26;95%CI 1,47 to 7,24;p 0,004), atherosclerotic cardiovascular disease (OR 2,11;95%CI 1,03 to 4,29;p 0,040), non-atherosclerotic cardiovascular disease (OR 6,40;95%CI 2,25 to 18,21, p<0,001) and malignancy (OR 5,09;95%CI 2,28 to 11,34;p< 0,001), were identified as comorbidities associated with in hospital-mortality. Age >65 years (OR 1,87;95%CI 1,05 to 3,34;p 0,033), male sex (OR 2,86;95%CI 1,58 to 5,17;p<0,001), obesity (OR 1,82;95%CI 1,04 to 3,18;p 0,034) and obstructive sleep apnea (OR 5,26;95%CI 1,60 to 17,25;p 0,006) were associated with severe COVID-19 disease. Conclusions: Previous cardiovascular disease and malignancy are risk factors of in-hospital mortality while obesity and obstructive sleep apnea are associated with severe COVID-19 disease in hospitalized patients. Age >65 years and male sex are associated with both.

17.
Journal of Population Therapeutics and Clinical Pharmacology ; 30(3):E1-E10, 2023.
Article in English | Web of Science | ID: covidwho-2310075

ABSTRACT

Background: At the peak of the viral season, World Health Organization ranked respiratory syncytial virus (RSV) as a major cause of acute respiratory infections in more than 60% of children and more than 80% of infants younger than one year. The current study is the first in the governorate of Was it to investigate respiratory syncytial virus subtypes. The objectives of the study were to estimate the frequency of respiratory syncytial virus in children <5 years old and to recognize some potential risk factors that might be associated with respiratory tract infections.Methodology: A cross sectional study with conventional reverse transcription polymerase chain reaction was performed on nasopharyngeal swabs from 158 pediatric patients. We compared the demographic and clinical characteristics of the patients aged 15 days to 60 months hospitalised with RTIs or seen at private clinics (cases, n = 158) and control children (n = 40) with non-respiratory symptoms during the respiratory season of 2021-2022. Pearson's chi-square (x2) model was applied, and P < 0.05 was considered significant.Results: RSV nucleic acid was detected in 15 (9.49%) of the 158 clinical specimens after amplification of the F gene. The identity of these amplified fragments was confirmed as human respiratory syncytial virus subtype B by sequencing. Except the clinical presentation there was no overall association between negative and positive cases while breast feeding and family history of the same condition when comparing the control and positive cases showed statistically significant.Conclusions: conventional PCR was successfully detected the subtype B of h RSV while it may not the appropriate PCR type for subtype A detecting or that the RSVB was the only subtype circulated in 2021-2022 winter.

18.
J Clin Med ; 12(8)2023 Apr 18.
Article in English | MEDLINE | ID: covidwho-2300078

ABSTRACT

BACKGROUND AND OBJECTIVES: During the COVID-19 pandemic, a possible overlap of obesity and COVID-19 infection has raised concerns among patients and healthcare professionals about protecting pregnant women from developing a severe infection and unwanted pregnancy outcomes. The aim of this study was to evaluate the associations of body mass index with clinical, laboratory, and radiology diagnostic parameters as well as pregnancy complications and maternal outcomes in pregnant patients with COVID-19. MATERIALS AND METHODS: Clinical status, laboratory, and radiology diagnostic parameters and pregnancy outcomes were analyzed for pregnant women hospitalized between March 2020 and November 2021 in one tertiary-level university clinic in Belgrade, Serbia, due to infection with SARS-CoV-2. Pregnant women were divided into the three sub-groups according to their pre-pregnancy body mass index. For testing the differences between groups, a two-sided p-value <0.05 (the Kruskal-Wallis and ANOVA tests) was considered statistically significant. RESULTS: Out of 192 hospitalized pregnant women, obese pregnant women had extended hospitalizations, including ICU duration, and they were more likely to develop multi-organ failure, pulmonary embolism, and drug-resistant nosocomial infection. Higher maternal mortality rates, as well as poor pregnancy outcomes, were also more likely to occur in the obese group of pregnant women. Overweight and obese pregnant women were more likely to develop gestational hypertension, and they had a higher grade of placental maturity. CONCLUSIONS: Obese pregnant women hospitalized due to COVID-19 infection were more likely to develop severe complications.

19.
Front Microbiol ; 14: 1096022, 2023.
Article in English | MEDLINE | ID: covidwho-2305471

ABSTRACT

Introduction: The protective effect of SARS-CoV-2 vaccines has become a global focus due to Omicron variant pandemic. The effects of various SARS-CoV-2 vaccines are diverse. However, studies on the effect of domestic vaccines on clinical characteristics in convalescent adult patients infected with the Omicron variant are lacking. Methods: In this retrospective, single-center cohort study, the effect of three domestic vaccines on clinical characteristics of convalescent adult patients infected with the Omicron variant was investigated in the initial largest outbreak of the Omicron variant infection between January and February 2022 in Tianjin, China. The primary endpoint was COVID-19 severity and the secondary endpoints were re-positive results on nucleic acid tests, liver and kidney function, and inflammation levels during recovery. Results: A total of 320 adult patients infected with the Omicron variant were enrolled, including 296 post-vaccination and 24 unvaccinated patients. The median age of the unvaccinated patients was higher than that of vaccinated patients, but no significant difference was detected in the sex composition ratio between the different groups. Binary logistic regression results suggested that Sinopharm and Sinovac vaccine was an independent protective factor for relieving the severity of the Omicron variant infection. Regrettably, the vaccines did not showed any protective effect on the liver and kidney function of convalescent adult patients. Three domestic vaccines significantly relieved inflammation and increased the SARS-CoV-2-specific antibody levels. Furthermore, Sinovac and CanSino vaccines had a better immune stimulation effect on increasing T lymphocytes levels in convalescent adult patients. In addition, three domestic vaccines have protective effects on preventing re-detectable positive (RP) result in convalescent adult patients. Conclusion: Although the three domestic vaccines cannot prevent the infection of the Omicron variant, it has a significant protective effect in adult patients. This study supports the policy of accelerating to vaccination worldwide combat the evolving and mutating SARS-CoV-2. Discussion: Omicron spreads faster and might escape antibodies more readily than previous variants, increasing the cases of reinfection and breakthrough infections in vaccinated people. Although vaccinated people are likely to have a much lower risk of severe disease from Omicron infection, many issues still need to be considered. Concerns about lower vaccine efficacy because of new variants might have changed our understanding of the COVID-19 endgame, disabusing the world of the notion that global vaccination is by itself adequate for controlling SARS-CoV-2 infection. The current data showed that vaccination with three domestic SARS-CoV-2 vaccines alleviates the disease severity of adult patients with COVID-19, reduces the inflammation level and the RP rate of convalescent adult patients, and enhances body's defense against the virus in convalescent adult patients. Moreover, our study has highlighted that a combination prevention approach of vaccination and public health measures would be an effective strategy.

20.
BMC Infect Dis ; 23(1): 237, 2023 Apr 17.
Article in English | MEDLINE | ID: covidwho-2302983

ABSTRACT

BACKGROUND: Omicron (B.1.1.529) is the fifth variant of concern of SARS-CoV-2, which has several subvariants. Clinical features of BA.1 and BA.2 infections have been described in the literature, but we have limited information about the clinical profile of BA.5, which caused the seventh wave in Iran. METHODS: A prospective observational study was conducted on the BA.5 confirmed patients referred to Imam Khomeini Hospital Complex, Tehran, Iran, from 11th to 31st August 2022. The patients were divided into the two groups of outpatients and hospitalized patients, and their clinical, radiological, and laboratory data and outcomes were recorded and analyzed. RESULTS: We included 193 patients with confirmed BA.5 infection, of whom 48 patients (24·8%) were hospitalized. The mean age of the patients was 45·3 ± 16·5 years, and 113 patients (58·5%) were female. The mean number of days patients had symptoms was 6·8 ± 2·4 days. The most common symptoms were weakness (69·9%), sore throat (67·4%), myalgia (66·3%), hoarseness (63·7%), headache (55·4%), fatigue (54·9%), and dry cough (50·3%). Fever and dyspnea were significantly more observed in the hospitalized patients (p < 0·0001). The COVID-19 vaccination rate was significantly lower in hospitalized patients than in outpatients (35/48-72·9% vs. 140/145 - 96·6%, p < 0·0001). The most common underlying diseases were hypertension (16·1%), diabetes mellitus (9·8%), and cardiovascular diseases (9·8%), all of which were significantly more common in hospitalized patients. Lung opacities were observed in 81·2% of hospitalized patients. By the end of our study, 1·5% of patients died despite receiving critical care services. CONCLUSIONS: Our findings suggested that BA.5 symptoms are more non-respiratory and usually improve within 7 days. Although the proportion of hospitalized patients is still significant, very few patients require intensive care. COVID-19 vaccination is effective in reducing the hospitalization rate. TRIAL REGISTRATION: Not applicable. This study is not a clinical trial.


Subject(s)
COVID-19 , Humans , Female , Adult , Middle Aged , Male , COVID-19/epidemiology , Iran/epidemiology , COVID-19 Vaccines , SARS-CoV-2 , Outpatients
SELECTION OF CITATIONS
SEARCH DETAIL